This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort CI
GENinCode says ROCA recommended as ovarian cancer risk test in England AN
GENinCode gets GBP57,000 in retail offer, well below maximum AN
GENinCode Raises GBP4 Million from Share Sale MT
GENinCode raises GBP4 million via placing and subscription AN
Genincode Plc Announces Placing And Subscription To Raise A Minimum Of £4.0 Mln RE
Aura eyes Tiris expansion; Kavango backs Pambili AN
GENinCode plc Agrees with the Food and Drug Administration to Create New Regulatory Class for Polygenic Risk scores and Transition Its Premarket Notification 510(K) Submission to A De Novo Pathway CI
EARNINGS: ASA interim profit plummets; Mycelx loss narrows, revenue up AN
Earnings Flash (GENI.L) GENINCODE Reports H1 Revenue GBP950,000 MT
Earnings Flash (GENI.L) GENINCODE Posts H1 Loss GBX-3.33 MT
GENinCode Plc Provides Revenue Guidance for the Second Half of 2023 CI
GENinCode Plc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Genincode plc Announces CARDIO inCode study on risk of incident Coronary Heart Disease CI
GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit DJ
GENinCode Submits Premarket Notification for US Commercial Distribution of Polygenic Test Kit MT
GENinCode plc Files its Premarket Notification with the Food and Drug Administration to Expand Its US Commercial Distribution of the Cardio InCode-Score Polygenic Test for the Risk Assessment and Prevention of Coronary Heart Disease CI
Certain Ordinary Shares of GENinCode Plc are subject to a Lock-Up Agreement Ending on 23-JUL-2023. CI
GENinCode Shares Rise Amid US Partnership with MedStar Health MT
GENinCode and MedStar collaborate on coronary heart disease testing AN
GENinCode Plc Announces Collaboration with MedStar Health CI
GENinCode annual loss widens; focuses on US, EU, and NHS in UK AN
GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GENinCode Plc Auditor Raises 'Going Concern' Doubt CI
Chart GENinCode Plc
More charts
GENinCode Plc is a United Kingdom-based predictive genetics company. The Company is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo and Thrombo Incode Reproductive Health. The Company's product portfolio draws on advanced genomic precision testing using polygenic (multiple genes) technology, molecular testing, genotyping, sequencing, and AI bioinformatics to risk assess patient DNA. Its predictive technology provides patients and physicians with global preventative care and treatment strategies. Its products combine genetic and clinical data to risk-assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. The Company’s wholly owned subsidiaries include GENinCode S.L.U. and GENinCode U.S. INC.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. GENI Stock
  4. News GENinCode Plc
  5. Earnings Flash (GENI.L) GENINCODE Reports H1 Revenue GBP950,000
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW